LOGIN  |  REGISTER
Astria Therapeutics

HCA Healthcare to Present at November Healthcare Conferences

October 17, 2024 | Last Trade: US$406.48 5.22 1.30

NASHVILLE / Oct 17, 2024 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA), is scheduled to present at the following healthcare conferences:

  • November 14, 2024 at 7:15am PT at the 2024 UBS Global Healthcare Conference at the Terranea Resort in Ranchos Palos Verdes, CA.
  • November 20, 2024 at 11:20am ET at the 2024 Wolfe Research Healthcare Conference at the Wolfe Offices in New York, NY.
  • November 21, 2024 at 8:00am CT at the 2024 Stephens Annual Investment Conference at the Grand Hyatt in Nashville, TN.

A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.

Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.

About HCA Healthcare

Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 188 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom.

All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB